Altre lingue 89bio, Inc.

Azioni

ETNB

US2825591033

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 23/04/2024			Variaz. 5gg	Var. 1 gen.
8,92 ^USD	-4,19%		-4,80%	-20,14%

17/04	89bio, Inc. nomina Martin Babler nel suo Consiglio di Amministrazione	CI
03/04	Un insider di 89bio ha venduto azioni per un valore di 575.153 dollari, secondo un recente documento della SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors	17/04
89bio, Inc. Appoints Martin Babler to Its Board of Directors	17/04
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	03/04
Sector Update: Health Care Stocks Gain Wednesday Afternoon	27/03
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	27/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	12/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)	11/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03
North American Morning Briefing : Stock Futures -2-	08/03
89bio to Participate in the Leerink Partners Global Biopharma Conference	05/03
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?	04/03
Top Premarket Gainers	04/03
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue 89bio, Inc.

Azioni

ETNB

US2825591033

Altre lingue

Filtri